ライフサイエンスコーパス: glycemia

1 eriod, respiratory period, body temperature, glycemia).

2 ate the association between dairy intake and glycemia.

3 on, restored insulin secretion, and improved glycemia.

4 high-fat diet-induced elevations in fasting glycemia.

5 centage of weight gain but did not influence glycemia.

6 of starch has implications for postprandial glycemia.

7 e, thereby lowering fasting and postprandial glycemia.

8 insulin sensitivity, insulin secretion, and glycemia.

9 f the GLP-1 receptor on gastric emptying and glycemia.

10 insulin analogs for the prandial control of glycemia.

11 h type 1 diabetes before and after improving glycemia.

12 on, heightened insulin levels, and decreased glycemia.

13 oxylase protein levels related strongly with glycemia.

14 uppresses gluconeogenic genes and normalizes glycemia.

15 k1/2 signaling, and the potential effects on glycemia.

16 release, gastric emptying, and postprandial glycemia.

17 f body fatness, markers of inflammation, and glycemia.

18 sponse, insulin sensitivity, and measures of glycemia.

19 t that this might not reflect differences in glycemia.

20 ntegrated measures of circulating nonfasting glycemia.

21 o feeding is a key regulator of postprandial glycemia.

22 s equivocal effect of PPAR-alpha agonists on glycemia.

23 e mice had only slightly elevated nonfasting glycemia.

24 ut the diurnal cycle, even in hypo- or hyper-glycemia.

25 ss hyperglycemia ratio, an index of relative glycemia.

26 l mechanisms involved in tissue responses to glycemia.

27 nce how accurately HbA1c reflects underlying glycemia.

28 y disease independent of kidney function and glycemia.

29 regulation maintains an appropriate range of glycemia.

30 eline kidney function but not independent of glycemia.

31 nsulin signaling, surprisingly showed normal glycemia.

32 ed adipose tissue thermogenesis and improved glycemia.

33 GF21, which include weight loss and improved glycemia.

34 y which exenatide can attenuate postprandial glycemia.

35 or reduce the production of GLP1 and affect glycemia.

36 did not lead to production of GLP1 or reduce glycemia.

37 issue function and the maintenance of normal glycemia.

38 both contribute to observed improvements in glycemia.

39 no differences in the incidence of impaired glycemia (16% in the probiotic group compared with 15% i

40 blood versus 733 +/- 277 mug/L (P < 0.0001), glycemia 5.44 +/- 0.7 versus 5.49 +/- 0.7 mmol/L (P = 0.

41 stprandial lipemia, but not for postprandial glycemia (6.0% and 15.4%, respectively); genetic variant

42 r studies have addressed whether near-normal glycemia (80-110 mg/dl) in this clinical setting improve

43 was negatively associated with a measure of glycemia (A1C; r = -0.44, P = 0.006) and positively asso

44 ic dogs resulted in normalization of fasting glycemia, accelerated disposal of glucose after oral cha

45 Prospective consumption (P = 0.07) and glycemia after an oral-glucose-tolerance test (P = 0.10)

46 and near-normal postprandial insulinemia and glycemia after correcting excessive postprandial hypergl

47 Improvements in fasting glycemia after GB-IL were mitigated with exendin-9, a GL

48 ontrolled trials measuring peak postprandial glycemia after isoenergetic replacement of glucose, sucr

49 fast (P < 0.01) and did not adversely affect glycemia after lunch or dinner.

50 ificant heterogeneity to this progression of glycemia after onset of diabetes, yet the factors that i

51 c insulin action decreases fasting glycemia, glycemia after pyruvate injection, and PEPCK protein exp

52 Normalization of glycemia after SPK shows no significant improvement in n

53 having 2 risk alleles and a history of poor glycemia and 1.54 (95% CI, 0.72-3.30) for participants w

54 .8% of patients experienced impaired fasting glycemia and 13.4% NODAT.

55 We investigated the association of glycemia and 43 genetic risk variants for hyperglycemia/

56 OLZ-IV caused a transient increase in glycemia and a higher rate of glucose appearance (R(a))

57 a on the effect of trajectories in long-term glycemia and all-cause mortality are lacking.

58 r of IL-1beta, has been suggested to improve glycemia and beta-cell function in patients with type 2

59 Glycemia and beta-cell function were assessed 1 week lat

60 tabolic actions of GLP-1 enable reduction of glycemia and body weight in diabetic and obese subjects,

61 ceptor (GLP-1R) agonists effectively improve glycemia and body weight in patients with type 2 diabete

62 ction was evaluated by measuring not-fasting glycemia and by performing an IVGTT on days 15 and 30 po

63 tions despite marked postprandial changes in glycemia and circulating insulin concentrations.

64 A positive correlation was observed between glycemia and clinical attachment loss (AL), whereas a ne

65 ant reductions in the primary outcome in the glycemia and dyslipidemia trials, but no significant eff

66 DPP-4 inhibition reduced glycemia and enhanced insulin levels and the incretin ef

67 The relationship between control of glycemia and gastric emptying (GE) is unclear.

68 diabetes after accounting for preconception glycemia and gestational glucose intolerance.

69 was required for maintaining normal fasting glycemia and glucose production.

70 prompted weight-independent improvements in glycemia and glucose tolerance secondary to augmented in

71 diabetes with periodontitis presented higher glycemia and glycated hemoglobin values in contrast to p

72 of metabolic syndrome (69.2 vs. 51.9%), fast glycemia and glycated hemoglobin, albuminuria, triglycer

73 mice exhibited significantly lowered fasting glycemia and heightened hepatic insulin sensitivity.

74 cts and four continuous outcomes (reflecting glycemia and hepatic insulin resistance) in 8,271 nondia

75 n between the APOB R3527Q variant and T2D or glycemia and highlight the asymmetry of the LDL-C-T2D re

76 PAHSAs reduce ambient glycemia and improve glucose tolerance and insulin sensi

77 This reduced fasting glycemia and improved glucose tolerance.

78 PAHSA administration in mice lowers ambient glycemia and improves glucose tolerance while stimulatin

79 Treatment of obese mice with PAHSAs lowers glycemia and improves glucose tolerance while stimulatin

80 Islet transplantation normalized glycemia and increased body and muscle weight; it was al

81 Destabilization of glycemia and increases in EIR were used as signs of reje

82 Compared with IS, IR subjects showed higher glycemia and insulin hypersecretion due to greater beta-

83 ns between baseline serum 25(OH)D and future glycemia and insulin resistance.

84 tory responses in leukocytes as well as 24-h glycemia and insulin secretion were analyzed.When compar

85 PTPR-gamma loss-of-function lowers glycemia and insulinemia by enhancing insulin-stimulated

86 ol-rich purple potatoes lowered postprandial glycemia and insulinemia compared to yellow potatoes.

87 y, was inversely associated with measures of glycemia and insulinemia in Brazilian adults without dia

88 physical activity at decreasing postprandial glycemia and insulinemia in healthy, normal-weight adult

89 Postprandial glycemia and insulinemia were measured in capillary plas

90 ts indicate that PPE alleviates postprandial glycemia and insulinemia, and affects postprandial infla

91 ression, and the use of therapies to control glycemia and lipidemia in its late stages.

92 s, have the potential to beneficially modify glycemia and long-term risks.

93 fects of endogenous GLP-1 on food intake and glycemia and may promote the further development of GLP-

94 ncreased after 10 days of hyperglycemia, and glycemia and muscle TRIB3 were both restored toward norm

95 A positive association between maternal glycemia and neonatal AA was observed across the whole r

96 en synthesis, with resultant improvements in glycemia and no evidence of hypoglycemia.

97 The role of intermediate-term and acute glycemia and of glucose variability on microvascular and

98 termined the association between gestational glycemia and offspring AA measured by MRI in the neonata

99 hepatic gammaATP correlated negatively with glycemia and oxidized LDL.

100 y U test) and a correlation analysis between glycemia and periodontal parameters were performed (Spea

101 es, a low-fat vegan diet appeared to improve glycemia and plasma lipids more than did conventional di

102 We examined the relation between gestational glycemia and prepregnancy body mass index (ppBMI) with o

103 NT and liraglutide coadministration improved glycemia and reduced steatohepatitis.

104 tive in nature, possibly fueled by worsening glycemia and regenerative processes.

105 looked roles for glucagon that extend beyond glycemia and supports a new role for alpha-cells as amin

106 portant contribution to long-term control of glycemia and T2DM once substantial surgery-induced weigh

107 (AL), whereas a negative correlation between glycemia and the number of teeth present was found (P <0

108 re associated longitudinally with changes in glycemia and the risk type 2 diabetes.

109 Plasmatic concentration of glycemia and TNF-alpha (n = 10) were analyzed by the glu

110 ant women with GDM had beneficial effects on glycemia and total and LDL-cholesterol concentrations bu

111 essibility on postprandial metabolism (e.g., glycemia) and to gain insight into the structural and bi

112 Spontaneous physical activity, 24-h glycemia, and 24-h insulin secretion did not differ betw

113 iovascular risk factors such as cholesterol, glycemia, and body weight was documented to increase ris

114 motility, gastrointestinal hormone release, glycemia, and EI.

115 er leads to glycogen accumulation, decreased glycemia, and hampered glucagon-induced gluconeogenesis,

116 ose of leptin below that needed to normalize glycemia, and if the ability of leptin to lower plasma g

117 ce developed similar body weight, steatosis, glycemia, and insulin levels after a glucose load; howev

118 ements in intraperitoneal glucose tolerance, glycemia, and islet function and also impaired insulin s

119 ith improved metabolic control (A1c, fasting glycemia, and metabolic tests) after IAK (14,779+/-3,800

120 tion between graft functionality assessed by glycemia, and MRI signal remains unclear.

121 i.p.) during 4 weeks had decreased fat mass, glycemia, and plasma levels of triglycerides and were pr

122 fibrosis-related diabetes, two indeterminate glycemia, and six impaired glucose tolerance.

123 an white persons across the full spectrum of glycemia, and the differences increase as glucose intole

124 s at doses devoid of effects on body weight, glycemia, and the THA.

125 antropyloroduodenal pressures, gut hormones, glycemia, appetite, and energy intake in obese subjects

126 associated with type 2 diabetes and fasting glycemia are enriched in these clustered islet enhancers

127 her the effects of GIP on energy balance and glycemia are regulated by glucocorticoids using pharmaco

128 tensive therapy (n = 711) aimed at achieving glycemia as close to the nondiabetic range as safely pos

129 n of OLZ resulted in a transient increase in glycemia as well as a higher R(a) in the basal period.

130 ucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and alb

131 ose was significantly lower at higher plasma glycemia, as was the appearance of d-xylose after the me

132 only for a short period, with a worsening of glycemia associated with continued decline in beta-cell

133 current study was to evaluate the effects of glycemia-associated genetic loci on islet function in vi

134 es remission at 2 years or of improvement in glycemia at 1 and 3 months.

135 ]), insulin sensitivity (Matsuda index), and glycemia at 12 months postpartum in 494 women undergoing

136 Despite normal feeding and fasting glycemia, BG4KO mice were glucose intolerant, demonstrat

137 Controlling glycemia, blood pressure, and cholesterol is important f

138 oduction during subsequent periods of normal glycemia but too brief to affect the HbA1c value are a m

139 ovements in insulin action and reductions in glycemia, but did not correspond with reductions in oxid

140 of sucrose and thereby suppress postprandial glycemia, but the evidence in humans is limited.

141 na (LCS/LCS) animals normalize their fasting glycemia by both increasing insulin secretion and regene

142 ose cotransporter 2 (SGLT2) inhibitors lower glycemia by enhancing urinary glucose excretion.

143 Insulin detemir (DET) reduces glycemia comparably to other long-acting insulin formula

144 weight, food intake, energy expenditure, and glycemia compared with Cnr1(flox/flox) control mice.

145 ipr(-/-) mice had similar energy balance and glycemia compared with Gipr(+)(/+) controls.

146 , or inflammatory cytokines, or perhaps poor glycemia control.

147 NIRKO mice revealed a glycemia-dependent impairment in the sympathoadrenal res

148 epatocyte injury and inflammation, decreased glycemia, deranged hepatic TCA cycle intermediate concen

149 raphics, risk factors, a latent variable for glycemia (diabetes status, fasting glucose, glycated hem

150 However, intervention of good glycemia directly with DNA methylation inhibitors (Azacy

151 a detection limit of 50 muM (useful for hypo-glycemia disease).

152 surgical patients suggested that near-normal glycemia dramatically improved outcomes compared with mo

153 GLP-1 potently diminished postprandial glycemia during acute and intermittent regimens.

154 enhanced DNL as a glucose sink in regulating glycemia during catch-up growth, which is blunted by exp

155 is, which is critical for the maintenance of glycemia during the adaptation to birth.

156 ments on obesity and the metabolic syndrome, glycemia, dyslipidemia, and cardiovascular risk and expl

157 ility of multiple drug classes that modulate glycemia effectively and minimize long-term complication

158 Ad-hACE2-eGFP significantly improved fasting glycemia, enhanced intraperitoneal glucose tolerance, in

159 Postprandial glycemia excursions increase after gastric bypass surger

160 glycemia for four months, followed by normal glycemia for four additional months, DNA methylation of

161 streptozotocin-induced diabetic rats in poor glycemia for four months, followed by normal glycemia fo

162 DCCT persist at certain loci associated with glycemia for several years during the EDIC Study and sup

163 for another 2 h and then maintaining normal glycemia for the following 6 h.

164 We compared the groups' glycemia from continuous glucose monitoring (CGM), beta

165 yco-/lipoxidation, nor markers of lenticular glycemia (fructose-lysine, glucospane) were elevated by

166 mice on a chow diet exhibited normal ambient glycemia, glucose tolerance and insulin sensitivity, and

167 ssociated with significant increases in mean glycemia, glucose variability, as measured by coefficien

168 ypothalamic insulin action decreases fasting glycemia, glycemia after pyruvate injection, and PEPCK p

169 w-density lipoprotein cholesterol level, and glycemia had been measured during the previous year and

170 Re-institution of good glycemia had no beneficial effect on hypermethylation of

171 etween incident heart failure and antecedent glycemia has not been evaluated.

172 ion and structure and their association with glycemia have not been explored in type 1 diabetes (T1DM

173 n = 10/group) with differing insulinemia and glycemia: healthy control subjects (euinsulinemia and eu

174 ta-cell dysfunction, insulin resistance, and glycemia, highlighting the need for consideration of the

175 In the subgroup of patients who lost weight, glycemia, homeostasis model of assessment of insulin res

176 Glycemia improved despite more reductions in concomitant

177 ponsiveness was reversed once the control of glycemia improved.

178 on, leading to a reduction in fed and fasted glycemia, improved glucose intolerance, decreased expres

179 betes, alphagp130KO mice had reduced fasting glycemia, improved glucose tolerance, reduced fasting in

180 e association of FH with diabetes status and glycemia in a large Amish population enriched for the FH

181 us animal studies, 1B6 was poor at reversing glycemia in a model of type 1 diabetes, whereas 1F11 ind

182 The factors regulating glycemia in a setting devoid of insulin and glucagon fun

183 ble approach to improve body composition and glycemia in adults with overweight and obesity.We evalua

184 Variability of glycemia in ambulatory conditions defined as the deviati

185 vidence that FBPase inhibitors could improve glycemia in animal models of type 2 diabetes.

186 HbA1c may systematically underestimate past glycemia in black patients with SCT and may require furt

187 ely 150 mg/dl is not inferior to near-normal glycemia in critically ill patients requiring nutrition

188 SSTR2 antagonism does not affect basal glycemia in D rats.

189 vitamin D supplementation in the lowering of glycemia in diabetes remains to be determined.

190 oglobin (HbA(1c)) is an important measure of glycemia in diabetes.

191 and is the standard measure used to monitor glycemia in diabetic patients, but results from studies

192 aches to normalize the extreme volatility of glycemia in diabetic patients.

193 nally, glucagon receptor antagonist improves glycemia in diet-induced obese angptl4 knockout mice wit

194 tion of glucagon and GLP-1 on resting EE and glycemia in healthy human volunteers.

195 stprandial insulin release is independent of glycemia in healthy individuals, despite differences in

196 beneficial effects of probiotics on maternal glycemia in healthy pregnant women.

197 eline were unaffected by acute variations in glycemia in healthy subjects and in type 2 diabetic pati

198 ubjects, providing the opportunity to reduce glycemia in human subjects with diabetes with a low risk

199 ith COOH-coated nanoparticles restore normal glycemia in immunocompetent diabetic mice for at least 6

200 tor play a role in the regulation of fasting glycemia in K(ATP)HI; and 2) the GLP-1 receptor may be a

201 Glycemia in non-fasted mice was measured weekly from day

202 isms accounting for this improved control of glycemia in overweight adults under conditions of one da

203 determine the role of GLP-1 in postprandial glycemia in patients with hyperinsulinemic hypoglycemia

204 Salsalate improves glycemia in patients with T2DM and decreases inflammator

205 cid sequestrant colesevelam HCl for reducing glycemia in patients with T2DM.

206 s combination will reduce weight and improve glycemia in patients.

207 ydrate exchange in the dietary management of glycemia in persons with diabetes, and studies have gene

208 gh maternal genotype, by increasing maternal glycemia in pregnancy, or through fetal genotype, by alt

209 Air pollution may contribute to abnormal glycemia in pregnancy.

210 are associated with quantitative measures of glycemia in pregnancy.

211 characterized fluctuations between states of glycemia in progressors to type 1 diabetes and studied w

212 Resveratrol has been reported to lower glycemia in rodent models of type 2 diabetes associated

213 insulin; this led to a steady correction of glycemia in the subsequent days.

214 uration studies show that salsalate improves glycemia in type 2 diabetes mellitus (T2DM).

215 less than 6.5%, mortality increased as mean glycemia increased; however, among patients with hemoglo

216 tal cancer cells); reduction in postprandial glycemia; increased insulin sensitivity; and effects on

217 For glycemia, increasing full-fat milk consumption was assoc

218 glucagon-like peptide-1 (GLP-1), might lower glycemia independent of increased beta-cell response or

219 ation of intestinal ECS reduced postprandial glycemia independently on intestinal glucose transport b

220 the gluconeogenic gene program, and lowered glycemia, indicating that a similar phenomenon occurs in

221 uence of the progressive increase in fasting glycemia induced by insulin resistance in the prediabeti

222 tion did not significantly affect markers of glycemia, inflammation, and adiposity as compared with n

223 luenced: HDL-cholesterol, LDL particle size, glycemia, insulinemia, inflammatory biomarkers, blood pr

224 The regulation of glycemia is challenged in healthy men and women after ex

225 paired; 2) the effect of DPP-4 inhibition on glycemia is likely to depend on adequate endogenous GLP-

226 nt expression of proinflammatory genes after glycemia is normalized ("hyperglycemic memory").

227 Comprehensive recording of glycemia is required for the generation of any measureme

228 rbohydrate content, even though postprandial glycemia is vastly influenced by glycemic index (GI).

229 se healthy patients) with no gradient across glycemia levels (20.6% of those with HbA1C<6%, 17.3% of

230 5 mmol/L, on 3 separate days, twice at lower glycemia (LOW) and once at higher values (HIGH).

231 onally adjusting for the latent variable for glycemia, low 1,5-AG levels (<6.0 mug/mL) were no longer

232 lobin levels and other indicators of average glycemia may be due to many factors but can be measured

233 in insulin secretion according to prevailing glycemia may improve diagnostic accuracy.

234 All plasma levels of glycemia measured by enzymatic technique as well as capi

235 The association of chronic glycemia, measured by HbA(1c), with long-term complicati

236 e possibility that additional factors beyond glycemia might contribute to the increased HF risk in di

237 inuria, or albuminuria is due to elements of glycemia not captured by mean HbA1c values.

238 rovide 90% power and a difference in fasting glycemia of 0.25 mmol/L.

239 cts across the range of maternal gestational glycemia on offspring abdominal adiposity (AA) in infanc

240 study was to determine the effect of plasma glycemia on the incretin effect.

241 A cycle activity but failed to lower fasting glycemia or endogenous glucose production.

242 with insulin resistance but not with fasting glycemia or glucose intolerance.

243 nd no effect of vitamin D supplementation on glycemia or incident diabetes.

244 e of FGF1 into the PVN was without effect on glycemia or other parameters, we conclude that the ARC-M

245 r-expressing Ldlr(-/-) mice independently of glycemia or plasma levels of total cholesterol and trigl

246 Hemoglobin A1c (HbA1c) reflects glycemia over 2-3 months and is the standard measure use

247 etic determinants associated with changes in glycemia over time might illuminate biological features

248 eptor agonist exenatide reduces postprandial glycemia, partly by slowing gastric emptying, although i

249 REM and AHINREM were associated with fasting glycemia, post-prandial glucose levels, and HOMA-IR in m

250 en without being able to reduce postprandial glycemia, products with slowly digestible starch can hav

251 rom 4 to100 mM (covering the hypo- and hyper-glycemia range, useful in diabetes).

252 Preadmission glycemia, reflected by hemoglobin A1c obtained at the on

253 mine and histidine decreased with increasing glycemia, reflecting, at least in part, insulin resistan

254 These neo-islets display glycemia-regulated insulin, beta-cell-specific transcrip

255 understand whether efficacy was mediated by glycemia regulation, a comparison with the sulfonylurea

256 ive strategies that are based on efficacious glycemia regulation, even if initiated days after stroke

257 abetic female NOD mice using measurements of glycemia, regulatory T-cell (CD4+CD25+Foxp3+) frequency,

258 ms that initiate adrenocortical responses to glycemia-related challenges are unknown.

259 tiate the adrenocortical response to various glycemia-related challenges.

260 Hindbrain catecholamine neurons distribute glycemia-related information throughout the forebrain.

261 lease of dietary glucose, is associated with glycemia-related problems such as diabetes and other met

262 nd improved further by including measures of glycemia, renal function, and diabetes mellitus treatmen

263 imeglimin treatment significantly decreased glycemia, restored normal glucose tolerance, and improve

264 in response plays a limited role in improved glycemia shortly after surgery.

265 The different responses to increasing mean glycemia support a personalized approach to glucose cont

266 ormin reduced fasting and glucose-stimulated glycemia, suppressed energy intake, and augmented total

267 maintained more stable afternoon and evening glycemia than did fasting.

268 ckade in the intestine reduced the increased glycemia that occurs following oral glucose administrati

269 ing macronutrient and modulates postprandial glycemia; the comparative effects of intraduodenal prote

270 ignificant effect on the relationship of ICU glycemia to mortality.

271 The effect of the randomized glycemia treatment on clinical and health status outcome

272 In the glycemia trial, targets of intensive and standard treatm

273 iraglutide combined therapy improved fasting glycemia upon short-term treatment and a chronic adminis

274 iodontal examination and preprandial fasting glycemia values were recorded for each individual.

275 meal and act on local receptors to regulate glycemia via a neuronal gut-brain axis.

276 GLP-1 receptor (GLP-1R) agonists control glycemia via glucose-dependent mechanisms of action and

277 investigated whether GIP regulates GLP1 and glycemia via IL6.

278 e systematically higher levels of nonfasting glycemia warrants further study.

279 Diabetic NOD mice conditioned with CT25 when glycemia was <500 mg/dL remained normoglycemic for 100 d

280 se production (EGP) was increased 25%, while glycemia was 0.9 +/- 0.7 mmol/l lower (P < 0.0001 vs. ba

281 tive in reversing diabetes in NOD mice whose glycemia was controlled with SC insulin pellets; these e

282 Moreover, postmeal glycemia was elevated and insulin release was blunted in

283 ce with streptozotocin-induced diabetes, and glycemia was initially controlled with exogenous insulin

284 o hyperinsulinemic-hypoglycemic clamps where glycemia was lowered slowly over 60-75 min.

285 Glycemia was measured by a glucose-oxidase method and bl

286 Glycemia was monitored to determine disease prevention a

287 ed on the NOD/ShiLtJ genetic background, and glycemia was monitored weekly up to 35 weeks of age to d

288 Continuously measured glycemia was more variable during the afternoon and even

289 ion of retinopathy by intensive treatment of glycemia was observed in ACCORD participants, whose aver

290 r regression showed that insulinemia-but not glycemia-was significantly associated with muscle insuli

291 limited knowledge on factors that influence glycemia, we aim to identify the clinical and genetic pr

292 onventional diabetes diet recommendations on glycemia, weight, and plasma lipids.

293 by enzymatic technique as well as capillary glycemia were collected in a cohort of mechanically vent

294 rance tests (OGTTs) from differing states of glycemia were compared within individuals for glucose an

295 t neurologic insult; biochemical measures of glycemia were less consistently related to MR imaging ch

296 Sustained benefits in glycemia were not identified following HCV clearance irr

297 ect was accompanied by improvement in plasma glycemia, whole body insulin sensitivity, plasma lipid l

298 terrelationships among different measures of glycemia will need to be considered in future analyses o

299 ing and opposite associations of gestational glycemia with weight and BMI in the first 36 mo of life

300 ffecting other FOXO1 target genes and lowers glycemia without concurrent steatosis.